Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNP | P00491 | 10/20 | 0.97 |
| ▸ | BLM | P54132 | 2/20 | 0.97 |
| ▸ | HBB | P68871 | 2/20 | 0.97 |
| ▸ | USP2 | O75604 | 1/20 | 0.97 |
| ▸ | TSHR | P16473 | 1/20 | 0.97 |
| ▸ | EDNRA | P25101 | 1/20 | 0.97 |
| ▸ | HTR2A | P28223 | 1/20 | 0.97 |
| ▸ | RECQL | P46063 | 1/20 | 0.97 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.97 |
| ▸ | HPRT1 | P00492 | 3/20 | 0.74 |
| ▸ | MEN1 | O00255 | 2/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.68 |
| ▸ | LMNA | P02545 | 1/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.68 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.68 |
| ▸ | VCP | P55072 | 1/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.68 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.68 |
| ▸ | POLG | P54098 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acyclovir SCHEMBL2269160 | 0.99 | PNP (1.00) | PNPBLMHBBUSP2TSHR | |
| Acyclovir SCHEMBL3664893 | 0.99 | PNP (1.00) | PNPBLMHBBUSP2TSHR | |
| Acyclovir SCHEMBL3175 | 0.99 | PNP (1.00) | PNPBLMHBBUSP2TSHR | |
| Acyclovir SCHEMBL29531632 | 0.97 | PNP (0.97) | PNPBLMHBBUSP2TSHR | |
| Acyclovir SCHEMBL16061083 | 0.97 | PNP (0.97) | PNPBLMHBBUSP2TSHR | |
| Acyclovir SCHEMBL40724 | 0.97 | PNP (0.97) | PNPBLMHBBUSP2TSHR | |
| Acyclovir SCHEMBL16060281 | 0.97 | PNP (0.97) | PNPBLMHBBUSP2TSHR | |
| Acyclovir SCHEMBL19031784 | 0.97 | PNP (0.97) | PNPBLMHBBUSP2TSHR | |
| Acyclovir SCHEMBL1690304 | 0.97 | PNP (0.97) | PNPBLMHBBUSP2TSHR | |
| Acyclovir SCHEMBL8068438 | 0.96 | PNP (0.95) | PNPBLMHBBUSP2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6930093-B2 | Use of ribofuranose derivatives against inflammatory bowel diseases | VALEANT RESEARCH & DEVELOPMENT (US) | 2005-08-16 | — | — | US | claimed |
| US-20050153908-A1 | Use of ribofuranose derivatives against inflammatory bowel diseases | ICN PHARMACEUTICALS SWITZERLAND LTD. | 2005-07-14 | — | — | US | claimed |
| US-20050153907-A1 | Use of ribofuranose derivatives against inflammatory bowel diseases | ICN PHARMACEUTICALS SWITZERLAND LTD. | 2005-07-14 | — | — | US | claimed |
| WO-2005004881-A1 | USE OF RIBOFURANOSE DERIVATIVES AGAINST INFLAMMATORY BOWEL DISEASES | ICN PHARMACEUTICALS SWITZERLAND LTD. (CH) | 2005-01-20 | — | — | WO | claimed |
| US-20050009768-A1 | Use of ribofuranose derivatives against inflammatory bowel diseases | ICN PHARMACEUTICALS SWITZERLAND AG | 2005-01-13 | — | — | US | claimed |
| US-20050009767-A1 | Use of ribofuranose derivatives against inflammatory bowel diseases | ICN PHARMACEUTICALS SWITZERLAND AG | 2005-01-13 | — | — | US | claimed |
| US-20050009766-A1 | Use of ribofuranose derivatives against inflammatory bowel diseases | ICN PHARMACEUTICALS SWITZERLAND LTD. | 2005-01-13 | — | — | US | claimed |
| WO-1997024357-A1 | PROCESS FOR SYNTHESIS AND PURIFICATION OF A COMPOUND USEFUL IN THE PREPARATION OF ACYCLOVIR | MALLINCKRODT CHEMICAL, INC. (US) | 1997-07-10 | — | — | WO | claimed |
| US-20160002240-A1 | NUCLEOSIDE ANALOG SALTS WITH IMPROVED SOLUBILITY AND METHODS OF FORMING SAME | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA | 2016-01-07 | — | — | US | disclosed |
| WO-2014145464-A1 | NUCLEOSIDE ANALOG SALTS WITH IMPROVED SOLUBILITY AND METHODS OF FORMING SAME | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA (US) | 2014-09-18 | — | — | WO | disclosed |
| US-6930093-B2 | Use of ribofuranose derivatives against inflammatory bowel diseases | VALEANT RESEARCH & DEVELOPMENT (US) | 2005-08-16 | — | — | US | disclosed |
| US-20050153908-A1 | Use of ribofuranose derivatives against inflammatory bowel diseases | ICN PHARMACEUTICALS SWITZERLAND LTD. | 2005-07-14 | — | — | US | disclosed |
| US-20050153907-A1 | Use of ribofuranose derivatives against inflammatory bowel diseases | ICN PHARMACEUTICALS SWITZERLAND LTD. | 2005-07-14 | — | — | US | disclosed |
| WO-2005004881-A1 | USE OF RIBOFURANOSE DERIVATIVES AGAINST INFLAMMATORY BOWEL DISEASES | ICN PHARMACEUTICALS SWITZERLAND LTD. (CH) | 2005-01-20 | — | — | WO | disclosed |
| US-20050009768-A1 | Use of ribofuranose derivatives against inflammatory bowel diseases | ICN PHARMACEUTICALS SWITZERLAND AG | 2005-01-13 | — | — | US | disclosed |
| US-20050009767-A1 | Use of ribofuranose derivatives against inflammatory bowel diseases | ICN PHARMACEUTICALS SWITZERLAND AG | 2005-01-13 | — | — | US | disclosed |
| US-20050009766-A1 | Use of ribofuranose derivatives against inflammatory bowel diseases | ICN PHARMACEUTICALS SWITZERLAND LTD. | 2005-01-13 | — | — | US | disclosed |
| WO-1997024357-A1 | PROCESS FOR SYNTHESIS AND PURIFICATION OF A COMPOUND USEFUL IN THE PREPARATION OF ACYCLOVIR | MALLINCKRODT CHEMICAL, INC. (US) | 1997-07-10 | — | — | WO | disclosed |
| WO-1997024357-A1 | PROCESS FOR SYNTHESIS AND PURIFICATION OF A COMPOUND USEFUL IN THE PREPARATION OF ACYCLOVIR | MALLINCKRODT CHEMICAL, INC. (US) | 1997-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160002240-A1 | NUCLEOSIDE ANALOG SALTS WITH IMPROVED SOLUBILITY AND METHODS OF FORMING SAME | ADAR, SLC28A1, SLC28A2 | PNP 6/4885BLM 1407/4885HBB 829/4885 |
| US-20050009766-A1 | Use of ribofuranose derivatives against inflammatory bowel diseases | RNASE1, ATIC, SI | PNP 24/4885BLM 2211/4885HBB 1877/4885 |
| US-20050153907-A1 | Use of ribofuranose derivatives against inflammatory bowel diseases | RNASE1, ATIC, SI | PNP 24/4885BLM 2211/4885HBB 1877/4885 |
| US-20050009767-A1 | Use of ribofuranose derivatives against inflammatory bowel diseases | RNASE1, ATIC, SI | PNP 24/4885BLM 2211/4885HBB 1877/4885 |
| US-20050153908-A1 | Use of ribofuranose derivatives against inflammatory bowel diseases | RNASE1, ATIC, SI | PNP 24/4885BLM 2211/4885HBB 1877/4885 |
| US-20050009768-A1 | Use of ribofuranose derivatives against inflammatory bowel diseases | RNASE1, ATIC, SI | PNP 24/4885BLM 2211/4885HBB 1877/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.